Excess weight and obesity are among the most widespread health risks globally. EraCal fights it: the University of Zurich and Harvard University spin-off, founded in 2018, develops novel appetite suppressants to combat obesity. Reducing appetite facilitates blood sugar and lipid control, reduces body weight and liver fat content, and facilitates healthy aging. The front-running program Era-379 was outlicensed to Novo Nordisk, the world-leader in anti-obesity pharmacotherapy, in January 2024 for €235M plus royalties.
